Chengdu New Radiomedicine Technology(CNRT) raised $14 million in a funding round led by BTG Asia, a subsidiary of London healthcare investor BTG plc. BTG, which contributed $11 million to the round, said it will collaborate with CNRT to develop its TheraSphere® nuclear cancer treatment in China. CNRT provides medical isotopes for tumor diagnosis and treatment. In 2013, BRT paid $200 million to acquire the TheraSphere technology, which is approved to treat hepatocellular carcinoma in many countries. Earlier this year, CNRT completed Phase I construction of its pilot plant.
Source: China Biotoday
